General Comments / Chat, page-10129

It was much easier for me to get investors interested in RAC when the opportunity for bisantrene was just as an orphan drug for AML than it is now when the opportunity is orders of magnitude larger. No matter what data you provide, people find it hard to believe that a little company from Australia could have a drug with as much potential as bisantrene.

The psychology of this effect is interesting, but the bigger the market potential gets and the more bisantrene is derisked, the more potential investors discount the opportunity. I half suspect if cardioprotection and m6A both bombed out in the clinic and all we were left with was AML, that the SP would go up.